Ποια είναι η τιμή για Syntara Limited (SNT)

Η τιμή για Syntara Limited (SNT) είναι $0.0183374

Ποια είναι η κεφαλαιοποίηση αγοράς για Syntara Limited (SNT)

Η κεφαλαιοποίηση αγοράς για Syntara Limited (SNT) είναι $27.51M

Syntara Limited (SNT) Τιμή και Κεφαλαιοποίηση Αγοράς

Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.

Η τιμή για SNT	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$3,533.21 $27.51M	NVDA	$5.301T	+19,267,682.92%
$3,088.63 $27.51M	AAPL	$4.634T	+16,843,248.04%
$2,761.44 $27.51M	GOOG	$4.143T	+15,058,953.48%
$2,392.44 $27.51M	MSFT	$3.589T	+13,046,679.38%
$1,904.25 $27.51M	AMZN	$2.857T	+10,384,438.20%

Η τιμή για SNT

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$3,533.21 $27.51M